← Back
$RYTM All transactions

RHYTHM PHARMACEUTICALS, INC.

M 10b5-1 Plan

$ Value

Shares

4,445

Price

Filed

Jul 3

Insider

Name

Garfield Alastair

Title

Chief Scientific Officer

CIK

0002027261

Roles

Officer

Transaction Details

Transaction Date

2025-07-01

Code

M

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

4,445

Footnotes

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. | The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted on June 25, 2024 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. | The restricted stock units vest as to 25% of the total restricted stock units on each of the first four anniversaries of July 1, 2024, subject to the Reporting Person's continued service on each such vesting date. The restricted stock units have no expiration date.

Filing Info

Accession No.

0001104659-25-065844

Form Type

4

Issuer CIK

0001649904

Garfield Alastair's History

Date Ticker Type Value
2026-02-01 RYTM M
2026-02-01 RYTM F $221K
2026-02-01 RYTM M $0
2025-07-02 RYTM $85K
2025-07-02 RYTM $388
2025-07-01 RYTM M
2025-07-01 RYTM M $0

Other Insiders at RYTM (90d)

Insider Bought Sold Last
German Christopher Paul
Corporate Controller & CAO
2026-02-01
Popovits Kimberly J 2026-04-01
Meeker David P
President and CEO
2026-02-01
Smith Hunter C
Chief Financial Officer
$703K 2026-02-05
Mazabraud Yann
EVP, Head of International
2026-04-01
Lee Jennifer Kayden
EVP, Head of North America
2026-02-01
Cramer Pamela J.
Chief Human Resources Officer
2026-02-01
Shulman Joseph
Chief Technical Officer
2026-02-01
Garfield Alastair
Chief Scientific Officer
2026-02-01